In the spring of 2017, the ADA Board of Directors convened an Insulin Access and Affordability Working Group (Working Group) to examine the full scope of the insulin affordability issue. Throughout 2017 and early 2018, the Working Group assembled existing public information about insulin prices and patient cost-sharing, and held discussions with multiple stakeholders at every level of the insulin supply chain to discuss how each entity affects the cost of insulin for the consumer.
In May 2018, the U.S. Senate Special Committee on Aging held a hearing titled Insulin Access and Affordability: The Rising Cost of Treatment, during which the Working Group’s Chair and ADA Chief Scientific, Medical and Mission Officer, Dr. William T. Cefalu, discussed the Working Group’s findings. The Working Group’s findings can be accessed in the June 2018 issue of Diabetes Care.
Watch the Senate Special Committee on Aging hearing.
Read the Working Group’s findings.